Most major medical guidelines say a 70-year-old woman does not need Pap smears at all, provided she has a history of normal screening results and no prior high-grade cervical abnormalities. Both the U.S. Preventive Services Task Force and the American Cancer Society recommend stopping cervical cancer screening at age 65 under those conditions. But that clean-cut advice hides real nuance, because a meaningful share of cervical cancer cases and deaths still occur in women well past 65, and the “adequate screening history” that qualifies someone to stop is more specific than many women realize.
What the Guidelines Actually Say
The USPSTF, whose recommendations drive most insurance coverage decisions in the United States, advises against screening women older than 65 who have had adequate prior screening and are not otherwise at high risk. “Adequate prior screening” has a precise definition: three consecutive negative Pap tests, or two consecutive negative co-tests (Pap plus HPV test), all within the 10 years before stopping, with the most recent test performed within the prior 5 years.1Annals of Internal Medicine. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement – Section: Clinical Considerations That is not simply “I’ve had Pap smears over the years.” It requires documented, consecutive negatives on a specific schedule.
The American Cancer Society issued an updated guideline in 2020 that largely agrees but adds an extra condition: the woman should have no history of a precancerous cervical lesion graded CIN2 or worse within the previous 25 years.2PubMed. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society If both of those boxes are checked, the ACS says all cervical cancer screening should stop, and it should not be restarted even if the woman later acquires a new sexual partner.
For a 70-year-old who meets those criteria, the straightforward answer is: you do not need any more Pap smears. But the guidelines assume a well-documented screening history. For many older women, that assumption does not hold.
When the “Stop at 65” Rule Does Not Apply
The exit criteria sound simple on paper, but several common situations knock a woman out of the “adequately screened” category and back into a gray zone where continued testing may be warranted.
- Incomplete records: If you cannot verify three consecutive negative Paps or two consecutive negative co-tests in the decade before you turned 65, you may not qualify. Women who switched doctors, moved between health systems, or had gaps in insurance often lack the documentation.
- Prior abnormal results: A history of CIN2 or CIN3 (moderate to severe precancerous changes) means continued surveillance, potentially for 25 years after the abnormality was treated. A 70-year-old who had a high-grade lesion treated at age 50, for instance, would still fall within that surveillance window under ACS guidance.
- Weakened immune system: Women living with HIV, on immunosuppressive therapy after an organ transplant, or on long-term corticosteroids face a higher risk of HPV-related cervical disease. Standard age-based exit rules do not apply to them.
- Never or rarely screened: A woman who has never had a Pap smear, or who was screened only sporadically, has no track record of normal results to rely on. For her, stopping at 65 makes little sense.
Any of these situations is a reason to discuss ongoing screening with a clinician rather than assume the default guideline covers you.
Why Cervical Cancer in Older Women Is Not Rare
One reason the stop-at-65 rule draws criticism is that cervical cancer keeps showing up in older women, and when it does, it tends to be caught late. A California-based study found that nearly one in five cervical cancer patients were 65 or older, and among those older patients, about 71% had late-stage disease at diagnosis, compared to 48% of younger women.3Cancer Epidemiology, Biomarkers & Prevention. Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California A U.S. national analysis told a similar story: among women diagnosed after age-based screening had ended, most were found at stage II or higher, with nearly a quarter presenting at stage IV.4PubMed Central. Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States
German registry data, corrected for hysterectomy rates (since women without a cervix cannot get cervical cancer), showed an incidence of about 23 new cases per 100,000 women aged 70 to 79.5PubMed Central. Epidemiology of cervical cancer in elderly women: Analysis of incidence, treatment, and survival using German registry data That hysterectomy correction matters, because raw incidence rates undercount cervical cancer in older age groups where many women have already had their cervix removed. Globally, the share of cervical cancer deaths occurring in women over 60 has been rising, climbing from about 42% of all cervical cancer deaths in 1990 to over 47% in 2021.6PubMed Central. Global, regional, and national epidemiology of cervical cancer in elderly women from 1990 to 2021 and its prediction to 2035
These numbers do not mean the guidelines are wrong for adequately screened women. They do suggest that the population of older women who slip through gaps in screening is large enough to matter.
HPV Can Linger for Decades
Cervical cancer is driven by persistent infection with high-risk strains of HPV. Younger women clear most HPV infections within a year or two, but the virus can apparently hide in the body at very low levels for decades. Animal models suggest that HPV can sit dormant in the base layer of cervical cells and reactivate when the immune system’s control weakens.7PubMed Central. Evidence and impact of human papillomavirus latency In older women, immune function naturally declines, and there is evidence that HPV detected in postmenopausal women may represent reactivation of a long-dormant infection rather than a newly acquired one. The viral load can drop below what standard tests detect, meaning a woman can test negative for HPV for years and still harbor a small reservoir of infected cells that later re-emerges.8The Journal of Infectious Diseases. Human Papillomavirus in Older Women: New Infection or Reactivation?
This reactivation phenomenon is one of the strongest scientific arguments for questioning whether a clean screening record before age 65 truly guarantees safety afterward. It does not mean every older woman is at high risk. But it does mean that a negative HPV test at age 60 is not an airtight guarantee of an HPV-free cervix at 75.
After a Hysterectomy
If your uterus and cervix were removed for a non-cancerous reason (fibroids, heavy bleeding, uterine prolapse), you generally do not need Pap smears at any age. The USPSTF has specifically stated that women without a cervix do not require Pap testing, unless the hysterectomy was performed because of cervical cancer or precancerous cervical changes.9JAMA. Cervical Cancer Screening Among Women Without a Cervix Despite this, a substantial number of post-hysterectomy women continue getting Pap smears. One study found that among older women who had undergone hysterectomy, having had a Pap smear within the past two years was one of the strongest predictors of intending to get another one, suggesting force of habit and routine medical inertia drive unnecessary testing.10PubMed. Correlates of intent to seek unnecessary pap tests among elderly women
If you had a supracervical (also called subtotal) hysterectomy, your cervix was left in place, and standard screening recommendations still apply. Many women are unsure which type of hysterectomy they had. If there is any doubt, a clinician can check with a speculum exam or review surgical records.
Overscreening Is Surprisingly Common
While some older women are underscreened, others continue getting Pap smears they no longer need. A large national study estimated that roughly 46% of older women eligible to stop screening were still being overscreened for cervical cancer.11JAMA Network Open. Geographic Variation in Overscreening for Colorectal, Cervical, and Breast Cancer Among Older Adults Overscreening was more common in women who had a regular source of care, were married, had higher education, and lived in metropolitan areas. Black and Hispanic women were also more likely to be overscreened, possibly reflecting clinician concerns about disparities in cervical cancer outcomes.
Unnecessary Pap smears are not free of consequence. Pelvic examinations cause discomfort or pain in a median of about 35% of women, and a similar proportion report anxiety, embarrassment, or fear related to the procedure.12PubMed. Screening pelvic examinations in asymptomatic, average-risk adult women: an evidence report for a clinical practice guideline from the American College of Physicians Beyond discomfort, a false-positive result can trigger colposcopy, biopsies, and follow-up procedures that carry their own physical and psychological costs, all for a cancer that, in a truly well-screened woman, is extremely unlikely.
A separate analysis of screening patterns in women ages 30 to 64 found that over 60% of those nearing the screening exit age were being rescreened within three years, many of whom were likely being tested more frequently than guidelines recommend.13PubMed Central. Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014 The pattern suggests that both patients and clinicians find it hard to step away from routine screening, even when the evidence supports doing so.
The Pap Test’s Limitations After Menopause
One underappreciated issue is that the Pap smear itself becomes a less reliable tool in postmenopausal women. After menopause, declining estrogen levels cause cervical and vaginal tissue to thin, which changes how cervical cells appear under a microscope. A Pap smear in this setting is more likely to produce an unclear or unsatisfactory result. Research has found that conventional cytology is about twice as likely to miss significant precancerous lesions (CIN2 or CIN3) in postmenopausal women compared to younger women, and that most women with those lesions on the cervix display normal cytology.14PubMed Central. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study
HPV testing is substantially more sensitive. A systematic review calculated that HPV DNA testing detected about 90% of high-grade lesions, compared with roughly 73% for cytology at the standard threshold.15PubMed. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies For older women who do need continued screening, primary HPV testing or co-testing (HPV plus Pap) is a more reliable choice than a Pap smear alone.
Self-Sampling as an Emerging Option
One of the practical barriers to cervical screening in older women is the speculum exam itself. Postmenopausal anatomy can make the procedure uncomfortable, and some women simply avoid it. Self-sampling for HPV, where a woman collects her own vaginal sample at home using a brush or swab, is gaining traction as an alternative. A systematic review focusing on women 65 and older found that self-sampling appeared feasible in this age group and may reduce barriers related to postmenopausal anatomy and speculum discomfort.16PubMed Central. Cervical cancer screening strategies in women 65 years and older in the human papillomavirus era: A systematic review and meta-analysis of human papillomavirus-based testing and self-sampling approaches
A pilot study looking at acceptability across age groups found that older women were actually less afraid of hurting themselves during the self-collection procedure than younger women were. Most participants across all ages found the self-sampling brush easy to understand and use, and a majority preferred it to clinician-collected samples, citing the ability to choose when and where to do it.17PubMed Central. Age-related acceptability of vaginal self-sampling in cervical cancer screening at two university hospitals: a pilot cross-sectional study Self-sampling does not replace the Pap smear directly; it tests for HPV, and a positive result still requires follow-up with a clinician. But as a first step for older women who might otherwise skip screening altogether, it has clear appeal.
What Drives the Decision to Keep Screening
Research into why older women seek Pap tests they may not need reveals a mix of habit, perception, and clinician influence. Among women without a uterus who still intended to get a Pap smear, the perceived opinion of their doctor was one of the strongest motivators. Women who believed their doctor thought the test was a good idea were roughly seven times more likely to intend to get one, regardless of whether it was medically necessary.10PubMed. Correlates of intent to seek unnecessary pap tests among elderly women Among women with an intact cervix, the perceived risk of developing cervical cancer and belief in the importance of the test were also strong predictors of continued screening intent.
This means the conversation between you and your clinician matters more than any guideline published in a journal. If your doctor has not explicitly discussed stopping cervical screening with you, and if the test keeps appearing on your visit checklist by default, you may be getting screened out of inertia rather than medical necessity. It is worth asking directly: given my screening history and risk factors, do I still need this?
Life Expectancy and Competing Health Priorities
Screening guidelines are designed for populations, not individuals. A healthy 70-year-old with a life expectancy of 15 or more years faces a different calculus than a 70-year-old managing serious chronic illness. The benefit of cancer screening depends on living long enough for a slow-growing cancer to cause harm, and cervical cancer generally takes years to develop from a precancerous state. Experts have noted that screening should be reconsidered at any age if life expectancy is limited, because the harms of unnecessary procedures and follow-up can outweigh a benefit that may never materialize.18PubMed. Cervical cancer screening in menopause: when is it safe to exit?
There is no bright-line rule for this. A woman in excellent health at 70, who was never adequately screened, could reasonably benefit from catch-up screening. A woman at 70 with advanced heart failure or dementia gains almost nothing from a Pap smear but still bears the discomfort and anxiety of the test. The decision should weigh overall health, not just age.
Racial Disparities and Screening Gaps
The assumption that most women reaching 65 have been adequately screened does not hold equally across populations. Black women in the United States have historically had higher rates of cervical cancer and higher mortality from it, driven partly by disparities in access to consistent screening throughout their lives. Some researchers have argued that current guidelines, by recommending uniform cessation at 65, may worsen these disparities by cutting off screening at the very point where accumulated gaps leave certain groups most vulnerable.19PubMed Central. It’s time to re-evaluate cervical Cancer screening after age 65 The same critique applies to immigrant women, uninsured women, and others who may have had inconsistent access to gynecologic care during their screening-age years.
For a 70-year-old woman in any of these groups, the question is not really whether the guidelines say she can stop. The question is whether she ever had the documented record of normal results that the guidelines require before stopping. Without that record, the guideline’s permission to stop does not apply.
Screening Outside the United States
International guidelines vary in their upper age limits, a reminder that the stop-at-65 threshold is partly a policy judgment rather than a hard biological cutoff.20Current Diagnostic Pathology. Call and recall cervical screening programme: Screening interval and age limits The UK’s National Health Service stops inviting women for screening at age 64. Australia screens until 74 using primary HPV testing with five-year intervals. The Netherlands screens until 60. These differences reflect different modeling assumptions about cost-effectiveness, population HPV prevalence, and healthcare system structures rather than fundamentally different biology. If you are a 70-year-old woman living outside the United States, your country’s exit age may be different, and the reasoning behind it will vary.
When an Older Study Still Matters
A 1988 study of low-income elderly women who received Pap smears found abnormal results (malignant or premalignant) in about 1 out of every 74 women screened. The researchers estimated that the early detection gained from screening this population saved roughly 3.7 years of life per 100 tests performed, at a cost of about $2,874 per year of life saved, a ratio that was considered favorable even in that era.21JAMA. The Cost-effectiveness of Cervical Cancer Screening for Low-Income Elderly Women The study is dated, and screening technology has improved since then, but its core finding holds an insight that still matters: among older women who have not been reliably screened, the yield of testing is higher than you might expect. The women most likely to benefit from screening after 65 are exactly those who were least likely to have been screened before 65.